SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 117 filers reported holding SYNDAX PHARMACEUTICALS INC in Q2 2021. The put-call ratio across all filers is 1.53 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2021 | $60,680,000 | +167.3% | 2,772,062 | +133.3% | 4.67% | +157.1% |
| Q3 2021 | $22,705,000 | +11.3% | 1,188,135 | 0.0% | 1.82% | -3.4% |
| Q2 2021 | $20,400,000 | -36.4% | 1,188,135 | -17.2% | 1.88% | -26.9% |
| Q1 2021 | $32,088,000 | +2.7% | 1,435,045 | +2.1% | 2.57% | +7.0% |
| Q4 2020 | $31,248,000 | +60.4% | 1,405,045 | +6.4% | 2.41% | +37.6% |
| Q3 2020 | $19,484,000 | -0.4% | 1,320,045 | 0.0% | 1.75% | +1.8% |
| Q2 2020 | $19,563,000 | +80.0% | 1,320,045 | +33.2% | 1.72% | +39.4% |
| Q1 2020 | $10,868,000 | – | 990,711 | – | 1.23% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kynam Capital Management, LP | 1,932,800 | $33,592,000 | 10.90% |
| Aisling Capital Management LP | 1,025,000 | $17,815,000 | 9.61% |
| Frazier Life Sciences Management, L.P. | 3,195,403 | $55,536,000 | 4.73% |
| Paradigm Biocapital Advisors LP | 701,356 | $12,190,000 | 3.22% |
| SPHERA FUNDS MANAGEMENT LTD. | 1,277,413 | $22,201,000 | 3.14% |
| Nantahala Capital Management | 2,692,303 | $46,792,000 | 2.07% |
| Avidity Partners Management LP | 4,823,400 | $83,831,000 | 1.75% |
| DAFNA Capital Management LLC | 371,987 | $6,465,000 | 1.68% |
| ACUTA CAPITAL PARTNERS, LLC | 206,126 | $3,582,000 | 1.67% |
| BVF INC/IL | 2,394,714 | $41,620,000 | 1.66% |